

# Handelsbanken Helse Tema

The fund is actively managed and invests globally in equities issued by companies within the healthcare sector. As a result, the fund has a currency exposure to these markets. The healthcare sector refers to the pharmaceutical, medical technology, biotech, service and other healthcare-related branches. The thematic investment strategy provides for investments that occur in a limited area in which development is deemed to result in a structural change to the economy and society. This change provides favorable conditions for companies active within the area to create profitable growth over time. For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab. The fund is reported as an Article 9 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).

## Performance

05.01.2026

YTD	1 week	1 mth.	3 mån	1 year	5 years	10 years
-1.22%	-1.39%	-1.21%	6.58%	-0.78%	52.78%	181.80%


## Average performance

Average. perf.	2 years	3 years	5 years	10 years
Fund <sup>1</sup>	7.69%	8.09%	9.65%	11.59%
Index <sup>2</sup>	7.10%	6.90%	10.59%	10.16%

<sup>1</sup> Calculated on the fund's monthly closing price

<sup>2</sup> Benchmark index: Solactive ISS ESG DM Health Care UCITS Index NTR. The information in the table refers to the benchmark index valid at any given time. In the event the fund has previously had other benchmark indexes, this information can be found in the fund's annual report.

## Fem års utveckling



## Portfolio



Stocks	95.30%
Bonds and Cash	4.70%
Senast uppdaterad: 30.11.2025	

United States	68.61%
United Kingdom	6.80%
Switzerland	5.54%
France	4.36%
Belgium	3.28%
Japan	2.37%
Denmark	2.16%
Netherlands	1.84%
China	1.64%
Other	3.41%

Senast uppdaterad: 30.11.2025

## Fund manager



### Christopher Sundman

Experience in the fund industry 1987.  
Portfolio Manager since 1 August 2022.



### Caroline Banér

Experience in the fund industry 2009.  
Portfolio Manager since 1 October 2024.

Main category	
Risk	4
Rate	466.47 (05.01.2026)
Reporting Currency	NOK
Handel	Daily
Total Rating™	★★★★
Minimum investment	0 NOK
Monthly savings	-
Handel på internet	No
Management Fee	1.5%
Entry charge	0%
Exit charge	0%
Fund assets	26,689 MNOK
Distribution per fund unit	-
Utdelningsdatum	-
Fund, date of launch	01.12.2000
Share class, date of launch	02.03.2015

## Largest holdings

Eli Lilly and Co	9.70%
Johnson & Johnson	6.55%
AstraZeneca PLC	6.07%
Thermo Fisher Scientific Inc	5.53%
AbbVie Inc	5.38%
Cencora Inc	3.81%
Boston Scientific Corp	3.64%
Merck & Co Inc	3.36%
UCB SA	3.13%
HCA Healthcare Inc	2.94%

Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. [Summary of investors' rights](#).

The prospectus and key information are available for the funds at [handelsbanken.no/fond](#).

[www.handelsbanken.se/funds](#)

**Handelsbanken**